Anzeige
Meldung des Tages: Gold über 5.000 USD verändert die Wirtschaftlichkeit grundlegend!

Teva Pharmaceutical Aktie (ADR) News

Aktie
WKN:  883035 ISIN:  US8816242098 US-Symbol:  TEVA Branche:  Pharmazeutika Land:  Israel
32,14 $
+0,00 $
0,00%
27,065 € 01:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
31,15 Mrd. €
Streubesitz
39,66%
KGV
-15,52
Dividende
0,071 €
Dividendenrendite
0,27%
Faktor
1
Originalaktie
IL0006290147
neu: Nachhaltigkeits-Score
58 %
Weiter aufwärts? Long handeln - Jetzt mit Hebel 9,22: UQ3MMV
Werbung

Teva Pharmaceutical Aktie (ADR) News

05.05.25 - GlobeNewswire
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)
The U.S. FDA has approved SELARSDI ™ ( ustekinumab-​aekn ) as interchangeable with the reference biologic Stelara ® ( ustekinumab ) in all presentations matching the reference ...
07.04.25 - GlobeNewswire
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
EPYSQLI ® (eculizumab-​aagh) is now available to patients living with difficult-​to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome ...
07.04.25 - GlobeNewswire
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-​related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine ...
31.03.25 - GlobeNewswire
New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 ...
27.03.25 - GlobeNewswire
Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available ...
27.03.25 - GlobeNewswire
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first ...
03.03.25 - GlobeNewswire
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March
TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and ...
27.02.25 - GlobeNewswire
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals
The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states
25.02.25 - GlobeNewswire
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder
UZEDY is currently approved in the US as a subcutaneous long-​acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment ...
22.02.25 - GlobeNewswire
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET
21.02.25 - GlobeNewswire
Der Patient steht an erster Stelle: Warum Europa handeln muss, um den Zugang zu Arzneimitteln zu sichern
AMSTERDAM, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Laut einer neuen Studie von Teva Pharmaceuticals Europe werden 46 % der Generika auf der EU-Liste der kritischen ...
21.02.25 - GlobeNewswire
Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has ...
18.02.25 - GlobeNewswire
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)
TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live ...
18.02.25 - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and ...
17.02.25 - Boersia.de
Teva Pharmaceutical Aktie: Ernsthafte Fragezeichen?
Der israelische Pharmakonzern Teva Pharmaceutical Industries verzeichnet aktuell eine rückläufige Entwicklung an der Börse. Der Aktienkurs liegt derzeit bei 15,45 EUR und weist ...
29.01.25 - GlobeNewswire
Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth
2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; ...
27.01.25 - GlobeNewswire
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and ...

Newssuche

Videos

newspaper
01:40 Uhr +0,18%
Wahnsinn! Warum Daytrader im FDAX oft verlieren
Ab Montag, dem 2. Februar börsentäglich ab 18 Uhr - FEIERABEND-​TRADING! Echte Trades auf Basis ... Mehr »